A Novel Immunosuppression Intervention for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Phase of Trial: Phase II
Latest Information Update: 01 May 2018
Price : $35 *
At a glance
- Drugs Basiliximab (Primary) ; Methylprednisolone (Primary) ; Mycophenolate mofetil (Primary) ; Prednisone (Primary) ; Tacrolimus (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- Acronyms NIPALS2013
- 11 Oct 2013 Planned End Date changed from 1 Jul 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov.
- 01 Oct 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 13 Aug 2013 Planned end date changed from 1 Jun 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov.